All In Biotech

Drug Trial Radar · NCT07228403

Efficacy and Safety Evaluation of Glepaglutide in Treatment of Short Bowel Syndrome

A 104-week, Multicenter, Open-label, Single-arm, Phase 3 Extension Trial Investigating the Long-term Safety and Efficacy of Glepaglutide in Adult Patients With Short Bowel Syndrome (SBS) Rolling Over From the EASE SBS 2 or 3 Trials

Last checked: Nov 20, 2026Latest source record: Jul 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

28

Actual

Start

Dec 11, 2025

Primary completion

Sep 18, 2028

Study completion Dec 31, 2028

Sponsor

Lead sponsor
Zealand PharmaIndustry
Sponsor type
Industry
First posted
Nov 14, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to understand the safety and efficacy of twice weekly glepaglutide 10 mg in adult patients with short bowel syndrome (SBS), who were previously enrolled in the EASE SBS 2 or EASE SBS 3 trials. Participants currently on these trials will be able to continue their glepaglutide treatment by enrolling in this EASE SBS 6 extension trial. The trial includes a 24-month treatment period, followed by a 4-week safety follow-up period. Participants will attend trial visits, where they may undergo heart tests (electrocardiogram (ECG)), vital sign checks, colonoscopies, blood and urine tests, and physical exams.

Conditions

  • Short Bowel Syndrome (SBS)

Interventions

  • Glepaglutide 10 mgDrug

    Administered twice weekly by subcutaneous injection for a maximum of 24 months

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of treatment emergent adverse events (TEAEs)Time frame: From baseline to the safety follow-up visit (A maximum of 25 months)

Locations

16 sites in 7 countries. Site status is shown where the registry gives one.

  • Mayo Clinic - PPDS

    Rochester, Minnesota

  • Lied Transplant Center at Nebraska Medical Center

    Omaha, Nebraska

  • Cleveland Clinic-9500 Euclid Ave

    Cleveland, Ohio

  • Vanderbilt University Medical Center-Tennesse-1211 21st Ave S

    Nashville, Tennessee

  • UZ Leuven - PPDS

    Leuven, Belgium

  • LHSC - University Hospital

    London, Ontario, Canada

  • AP-HP - Hôpital Beaujon

    Clichy, Hauts-de-Seine, France

  • Asklepios Klinik St. Georg

    Hamburg, Germany

  • Universitätsklinikum Frankfurt

    Frankfurt am Main, Hesse, Germany

  • Universitätsmedizin Rostock

    Rostock, Mecklenburg-Vorpommern, Germany

  • Universitätsklinikum Bonn

    Bonn, North Rhine-Westphalia, Germany

  • Charité - Universitätsmedizin Berlin

    Berlin, State of Berlin, Germany

  • Wojewódzki Szpital Specjalistycznyo im. M. Pirogowa w Lodzi

    Lodz, Poland

  • Szpital Skawina sp. z o.o. im. Stanley Dudricka

    Skawina, Lesser Poland Voivodeship, Poland

  • Samodzielny Publiczny Szpitala Kliniczny im. Prof. Witolda Orlowskiego CMKP

    Warsaw, Masovian Voivodeship, Poland

  • St Mark's Hospital (Central Middlesex Hospital)

    Ealing, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.